{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:06:48Z","timestamp":1774375608831,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rmed.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T17:44:45Z","timestamp":1560015885000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations"],"prefix":"10.1016","volume":"154","author":[{"given":"Remco S.","family":"Djamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-2478","authenticated-orcid":false,"given":"Mona","family":"Bafadhel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton A.M.","family":"Ermens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno M.","family":"van der Eerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.rmed.2019.06.005_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rmed.2019.06.005_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1378\/chest.121.5.1449","article-title":"Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD","volume":"121","author":"Miravitlles","year":"2002","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.rmed.2019.06.005_bib3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.rmed.2019.06.005_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.rmed.2019.06.005_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.005_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"The Lancet.Respir. Med."},{"issue":"20","key":"10.1016\/j.rmed.2019.06.005_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2019.06.005_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"The Lancet.Respir. Med."},{"issue":"9459","key":"10.1016\/j.rmed.2019.06.005_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)17907-0","article-title":"Outpatient antibiotic use in Europe and association with resistance: a cross-national database study","volume":"365","author":"Goossens","year":"2005","journal-title":"Lancet"},{"issue":"9560","key":"10.1016\/j.rmed.2019.06.005_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","article-title":"Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study","volume":"369","author":"Malhotra-Kumar","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.rmed.2019.06.005_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","article-title":"Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy","volume":"189","author":"Han","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMct1115170","article-title":"Antibiotic prevention of acute exacerbations of COPD","volume":"367","author":"Wenzel","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.005_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.rmed.2019.06.005_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1745-6215-13-82","article-title":"Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial","volume":"13","author":"Uzun","year":"2012","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.rmed.2019.06.005_bib15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.005_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2019.06.005_bib17","unstructured":"Isenberg HD. second ed. American Society of Microbiology Press, Washington DC, 2004."},{"key":"10.1016\/j.rmed.2019.06.005_bib18","author":"(EUCAST) ECoAST"},{"issue":"3","key":"10.1016\/j.rmed.2019.06.005_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200605-713OC","article-title":"C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease","volume":"175","author":"Dahl","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.005_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2019.06.005_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"The Lancet.Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.005_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","article-title":"Blood Eosinophils and Outcomes in Severe Hospitalised Exacerbations of COPD","volume":"150","author":"Bafadhel","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2019.06.005_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.005_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.08-0047","article-title":"Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD","volume":"134","author":"Stolz","year":"2008","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2019.06.005_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1378\/chest.13-1063","article-title":"Stable State MR-Proadrenomedullin Level Is a Strong Predictor for Mortality in COPD Patients","volume":"145","author":"Zuur-Telgen","year":"2014","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.rmed.2019.06.005_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0954-6111(03)00042-8","article-title":"Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis","volume":"97","author":"Kadota","year":"2003","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.rmed.2019.06.005_bib27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.rmed.2019.06.005_bib28","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.rmed.2019.06.005_bib29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.rmed.2019.06.005_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thoraxjnl-2014-205998","article-title":"A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation","volume":"70","author":"Corris","year":"2015","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s15010-008-8023-1","article-title":"Erythromycin resistance in Streptococcus pyogenes and macrolide consumption in a central Italian region","volume":"37","author":"Montagnani","year":"2009","journal-title":"Infection"},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib32","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/JCM.01454-08","article-title":"Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007","volume":"47","author":"Fenoll","year":"2009","journal-title":"J. Clin. Microbiol."},{"issue":"11","key":"10.1016\/j.rmed.2019.06.005_bib33","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1128\/AAC.48.11.4183-4188.2004","article-title":"Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Berg","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.rmed.2019.06.005_bib34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.06.005_bib36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2019.06.005_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/ajrccm.156.1.9612065","article-title":"Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells","volume":"156","author":"Takizawa","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2019.06.005_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119301933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:50:39Z","timestamp":1760615439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119301933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"alternative-id":["S0954611119301933"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.005","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}